Literature DB >> 12797114

Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector.

Sebastien Folliot1, Delphine Briot, Hervé Conrath, Nathalie Provost, Yan Cherel, Philippe Moullier, Fabienne Rolling.   

Abstract

BACKGROUND: Viral vector delivery of neurotrophic-expressing transgenes in the retina may retard or prevent the onset of blindness associated with photoreceptor degeneration. A key safety issue is to achieve regulated expression of these genes in the retina. The purpose of our study was to evaluate whether a single recombinant AAV-2 (rAAV) encoding for a tetracycline (Tet)-regulated destabilized reporter gene could provide quantitative profiles of gene regulation targeted to the rat neuroretina.
METHODS: A rAAV vector carrying a destabilized green fluorescent protein (dgfp) under a tet-regulatable promoter and the tetracycline-repressed transactivator (tTA) was generated (rAAVtetoff.dgfp) and administered intravitreally in nine Wistar rats. Retinas were monitored for 6 months using noninvasive fluorescence imaging and the animals were subjected to two cycles of doxycycline (Dox), a tetracycline analog. Eyes were ultimately examined by histology.
RESULTS: Intravitreal injection of rAAVtetoff.dgfp resulted in effective transduction of ganglion cells. Following full expression of the transgene in the absence of Dox, 95% of the GFP signal was shut down 48 h post Dox administration and the signal was undetectable 7 days later. Initial levels of GFP expression were restored 21 days after Dox administration ceased. This pattern of expression was repeated twice over a period of 6 months.
CONCLUSIONS: This report demonstrates that rAAVtetoff.dgfp intravitreally injected rats displayed tight and sustained long-term regulation of the reporter gene in ganglion cells. These findings may have important implications regarding rAAV-mediated gene therapy using neuroprotective approaches for retinitis pigmentosa and glaucoma. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797114     DOI: 10.1002/jgm.367

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  13 in total

1.  AAV gene transfer to the retina does not protect retrovirally transduced hepatocytes from the immune response.

Authors:  Marta Bellodi-Privato; Guylène Le Meur; Dominique Aubert; Alexandra Mendes-Madera; Virginie Pichard; Fabienne Rolling; Nicolas Ferry
Journal:  J Mol Med (Berl)       Date:  2004-03-24       Impact factor: 4.599

Review 2.  Gene therapy for ocular diseases.

Authors:  Melissa M Liu; Jingsheng Tuo; Chi-Chao Chan
Journal:  Br J Ophthalmol       Date:  2010-08-23       Impact factor: 4.638

Review 3.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 4.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

5.  Regulation of retinal function but nonrescue of vision in RPE65-deficient dogs treated with doxycycline-regulatable AAV vectors.

Authors:  Elsa Lhériteau; Lyse Libeau; Alexandra Mendes-Madeira; Jack-Yves Deschamps; Michel Weber; Guylène Le Meur; Nathalie Provost; Caroline Guihal; Philippe Moullier; Fabienne Rolling
Journal:  Mol Ther       Date:  2010-03-30       Impact factor: 11.454

6.  Republished review: Gene therapy for ocular diseases.

Authors:  Melissa M Liu; Jingsheng Tuo; Chi-Chao Chan
Journal:  Postgrad Med J       Date:  2011-07       Impact factor: 2.401

Review 7.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

8.  Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors.

Authors:  Y Han; Q A Chang; T Virag; N C West; D George; M G Castro; M C Bohn
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

Review 9.  Gene therapy targeting glaucoma: where are we?

Authors:  Xuyang Liu; Carol A Rasmussen; B'ann T Gabelt; Curtis R Brandt; Paul L Kaufman
Journal:  Surv Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 6.048

10.  Long-term inducible expression in striatal neurons from helper virus-free HSV-1 vectors that contain the tetracycline-inducible promoter system.

Authors:  Qingshen Gao; Mei Sun; Xiaodan Wang; Guo-Rong Zhang; Alfred I Geller
Journal:  Brain Res       Date:  2006-03-20       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.